ABSTRACT
The inhalation of antimicrobial agents to treat infections in the lung has been
of interest for decades [1]. As early as the 1950s, extemporaneously prepared
antimicrobial agents were aerosolized to treat pneumonia. These preparations
were often crude and not well tolerated by patients. Dosage, formulation
procedures, and stability assessment in these early reports were not consistent.
Although some successes were reported, the potential benefit of this route of
administration was not fully appreciated until the 1980s.
